Current President and CEO, Samir R. Patel, M.D., to remain as a member of the Company’s Board of Directors BOSTON and LONDON, ...

MacroGenics (NASDAQ: MGNX) Q4 2024 Earnings Call Mar 20, 2025, 4:30 p.m. ET ...

Former SVP and Franchise Head for US Oncology at Jazz Pharmaceuticals, with established track record for leading a portfolio ...

ALE.P02 has a potentially first-in-class tubulin inhibitor payload, while ALE.P03 features a topoisomerase I inhibitor. The funding round was led by OrbiMed, with co-leads Novo Holdings and Jeito ...

Fully enrolled LORIKEET, a randomized 150-patient Phase 2 study of lorigerlimab in combination with docetaxel in patients with mCRPCInitiating ...

Calcineurin inhibitors are topical and systemic immunosuppressants. They can help treat atopic dermatitis and autoimmune disorders such as lupus and psoriasis. They may also help prevent organ ...

NORTH CHICAGO, IL, USA I March 15, 2025 I AbbVie (NYSE: ABBV) today announced the final analysis of the confirmatory Phase 3 MIRASOL trial evaluating the ...

and novel agents (e.g. tirapazamine, EGFR inhibitors and other targeted agents) with radiotherapy will be examined. This article is part one of two articles. In the subsequent article, the general ...

This paper reports important findings on giant organelle complexes containing endosomes and lysosomes (termed endosomal-lysosomal organelles form assembly structures [ELYSAs]) present in mouse oocytes ...

Luveltamab tazevibulin demonstrated activity in an ongoing phase 2/3 trial of patients with FRα-positive, platinum-resistant ovarian cancer.